Summit Therapeutics Inc. COM is a security (CUSIP 86627T108) tracked across SEC portfolio filings. 231 institutional managers reported $2.1B on Form 13F as of 2026-06-30; 26 registered fund positions totaling $235.7M via N-PORT as of 2026-05-31.
Showing 15 of 231 managers by value.
| Manager | Location | Value | Shares |
|---|---|---|---|
| BAKER BROS. ADVISORS LP | NEW YORK, NY | $690.0M | 36,391,063 |
| FMR LLC | BOSTON, MA | $205.8M | 10,853,199 |
| VANGUARD GROUP INC | Valley Forge, PA | $195.5M | 11,177,220 |
| BlackRock, Inc. | New York, NY | $183.0M | 9,653,758 |
| STATE STREET CORP | BOSTON, MA | $133.3M | 7,028,160 |
| UBS Group AG | Zurich, V8 | $70.2M | 3,680,315 |
| GEODE CAPITAL MANAGEMENT, LLC | BOSTON, MA | $62.9M | 3,315,854 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | BALA CYNWYD, PA | $45.7M | 603,933 |
| D. E. Shaw & Co., Inc. | New York, NY | $42.5M | 2,242,229 |
| MORGAN STANLEY | NEW YORK, NY | $31.3M | 1,650,591 |
| Aberdeen Group plc | EDINBURGH, X0 | $24.7M | 1,693,626 |
| CITADEL ADVISORS LLC | MIAMI, FL | $20.1M | 441,743 |
| TWO SIGMA INVESTMENTS, LP | New York, NY | $18.6M | 981,185 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | SAN FRANCISCO, CA | $18.2M | 960,867 |
| SUPERSTRING CAPITAL MANAGEMENT LP | NEW YORK, NY | $16.9M | 892,873 |
Showing 15 of 26 fund positions by value.
| Fund | Registrant | Value | % of fund |
|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | T. ROWE PRICE HEALTH SCIENCES FUND, INC. | $112.8M | 103.53% |
| Fidelity Growth Company Fund | Fidelity Mt. Vernon Street Trust | $46.5M | 4.71% |
| VANGUARD EXTENDED MARKET INDEX FUND | VANGUARD INDEX FUNDS | $32.6M | 4.00% |
| Fidelity Contrafund | Fidelity Contrafund | $9.3M | 0.59% |
| Fidelity Advisor Health Care Fund | Fidelity Advisor Series VII | $8.6M | 29.73% |
| abrdn Healthcare Investors | abrdn Healthcare Investors | $8.1M | 71.23% |
| T. Rowe Price Health Sciences Portfolio | T. ROWE PRICE EQUITY SERIES, INC. | $6.9M | 103.84% |
| abrdn Life Sciences Investors | abrdn Life Sciences Investors | $4.5M | 80.54% |
| Fidelity Nasdaq Composite Index ETF | Fidelity Commonwealth Trust | $3.4M | 3.07% |
| T. Rowe Price Diversified Mid-Cap Growth Fund, Inc. | T. ROWE PRICE DIVERSIFIED MID-CAP GROWTH FUND, INC. | $3.0M | 7.15% |
| BlackRock Health Sciences Term Trust | BlackRock Health Sciences Term Trust | $2.2M | 21.78% |
| BlackRock Health Sciences Trust | BlackRock Health Sciences Trust | $1.5M | 28.53% |
| Large Cap Index Master Portfolio | Master Investment Portfolio | $1.3M | 0.36% |
| VANGUARD BALANCED INDEX FUND | VANGUARD VALLEY FORGE FUNDS | $1.3M | 0.22% |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND | VANGUARD INSTITUTIONAL INDEX FUNDS | $1.0M | 0.34% |